GME Meeting Planner
Event URL: https://onlinexperiences.com/Launch/Event/ShowKey=108338
Registrants can access the webcast using the link above. Please note, you will not be able to enter the site until the designated start time.
All course materials will be available for download from the "Handouts" tab once the webcast starts. Materials are not available in advance.
Jointly provided by Postgraduate Institute for Medicine and Global Medical Education.
This activity is supported by an independent educational grant from LivaNova
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists and psychologists engaged in the care of patients with dementia.
After completing this activity, the participant should be better able to:
- Discuss the prevalence of difficult to treat depression
- Use evidence-based treatments to achieve remission in major depression
- Outline novel targets including glutamate for treating major depression
- Describe treatments with innovative mechanisms including devices to treat major depression
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number –JA4008162-9999-20-2219-L01-P
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour. Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1 contact hour.
AAPA Credit Designation Statement
This activity is designated for 1 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Continuing Psychologist Education
Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility of the program.
This program offers 1.0 continuing education credits for psychologists.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
7:00 - 7:20 PM ET: "Diagnostic and Biological Underpinnings of Difficult to Treat Depression" - Charles Conway, MD (Wash U)
7:20 - 7:40 PM ET: "The Emerging Therapeutics for Difficult to Treat Depression" - Scott Aaronson, MD (U of Maryland)
7:40 - 8:00 PM ET: Q&A